Research news
- 24 January 2012
Government to seek public views on allowing prevention of mitochondrial diseases The Government has asked the HFEA to seek public views on a type of IVF designed to prevent mitochondrial diseases being passed from mother to child - 19 January 2012
New Centre for mitochondrial research to take our research forward A new £5.8 million research centre is to be set up that will continue research we spearheaded to develop techniques to prevent the inheritance of mitochondrial diseases - 17 January 2012
Highlights from the International Myotonic Dystrophy Consortium meeting A meeting in Florida has brought together more than 200 scientists and clinicians from around the world to discuss the latest research developments in myotonic dystrophy - 11 January 2012
Research improves diagnosis of facioscapulohumeral muscular dystrophy European scientists have shed new light on alternative diagnoses for some people who may at first appear to have facioscapulohumeral muscular dystrophy (FSHD) - 11 January 2012
Study to look into falls in people with inclusion body myositis Researchers in London have embarked on a study to better understand falls in people with inclusion body myositis (IBM) and if physiotherapy could help prevent them. - 6 January 2012
Gene therapy clinical trial for spinal muscular atrophy started Isis Pharmaceuticals has started a Phase 1 clinical trial of an antisense oligonucleotide drug called ISIS-SMNRx in patients with spinal muscular atrophy (SMA). - 19 December 2011
Summit secures funding for utrophin drug for Duchenne Summit plc has secured £1 million worth of funding from several US-based charities to manufacture a new formulation of a potential drug for Duchenne and Becker muscular dystrophies and conduct a Phase 1 clinical trial. - 30 November 2011
Ataluren extension trial for Duchenne about to start PTC Therapeutics has affirmed their commitment to develop ataluren to treat boys with Duchenne muscular dystrophy and announced progress in starting an extension trial in the UK, Europe, Israel and Australia. - 29 November 2011
Collaboration offers new hope for potential spinal muscular atrophy treatment Roche has signed a multi-million dollar agreement with PTC Therapeutics to develop drugs for spinal muscular atrophy - 28 November 2011
New advances in FSHD research Highlights from the FSH Society meeting in Boston including new insights into the cause of facioscapulohumeral muscular dystrophy and a new diagnostic test for FSHD type 2
